About bamlanivimab l histidine
Anti-SARS-CoV-2 monoclonal antibody
Used for
- Previously authorized in the United States for treating mild-to-moderate COVID-19 in certain high-risk patients.
- Use was limited to susceptible variants and is no longer routinely available.
Usual adult dose
Previously, a single 700 mg intravenous infusion for COVID-19 under emergency authorization.
Usual dose in children
Previously, a single 700 mg intravenous infusion for eligible patients aged 12 years or older weighing at least 40 kg.
Common side effects
- Infusion reactions, including fever, chills, nausea, or rash
- Allergic reactions, including anaphylaxis
- Diarrhea
- Dizziness
Important warnings
- Authorization was revoked after resistant variants became prevalent.
- Infusion reactions can occur during or after administration.
- Use was not authorized for patients hospitalized because of COVID-19 or requiring oxygen due to COVID-19.
Pregnancy
Human pregnancy data are limited; use depended on potential benefit and clinical circumstances.
Breastfeeding
Effects on breast milk and nursing infants are unknown.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.